LCS
Levin Capital Strategies Portfolio holdings
AUM
$1.02B
This Quarter Return
-15.75%
1 Year Return
+24.33%
3 Year Return
+82.04%
5 Year Return
+153.74%
10 Year Return
+220.71%
AUM
$4.54B
AUM Growth
+$4.54B
(-22%)
Cap. Flow
-$447M
Cap. Flow
% of AUM
-9.84%
Top 10 Holdings %
Top 10 Hldgs %
42.65%
Holding
327
New
47
Increased
53
Reduced
101
Closed
69
Top Buys
| 1 |
Bio-Rad Laboratories Class A
BIO
|
$130M |
| 2 |
Quest Diagnostics
DGX
|
$120M |
| 3 |
CommScope
COMM
|
$73.9M |
| 4 |
Textron
TXT
|
$66.4M |
| 5 |
CVS Health
CVS
|
$63.2M |
Top Sells
| 1 |
Merck
MRK
|
$166M |
| 2 |
Nokia
NOK
|
$116M |
| 3 |
General Dynamics
GD
|
$93.3M |
| 4 |
Pfizer
PFE
|
$88M |
| 5 |
Intel
INTC
|
$87.6M |
Sector Composition
| 1 | Financials | 19% |
| 2 | Healthcare | 14.48% |
| 3 | Technology | 13.52% |
| 4 | Consumer Discretionary | 10.91% |
| 5 | Consumer Staples | 10.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
326
Babcock & Wilcox
BW
$257M
| – | – |
-40,000
| Closed | -$41K |
|